Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312126611> ?p ?o ?g. }
- W4312126611 endingPage "2108" @default.
- W4312126611 startingPage "2108" @default.
- W4312126611 abstract "This study aimed to evaluate the efficacy of a new trivalent vaccine containing inactivated Porcine Circovirus 1-2a and 1-2b chimeras and a Mycoplasma hyopneumoniae bacterin administered to pigs around 3 weeks of age. This trivalent vaccine has already been proved as efficacious in a split-dose regimen but has not been tested in a single-dose scenario. For this purpose, a total of four studies including two pre-clinical and two clinical studies were performed. Globally, a significant reduction in PCV-2 viraemia and faecal excretion was detected in vaccinated pigs compared to non-vaccinated animals, as well as lower histopathological lymphoid lesion plus PCV-2 immunohistochemistry scorings, and incidence of PCV-2-subclinical infection. Moreover, in field trial B, a significant increase in body weight and in average daily weight gain were detected in vaccinated animals compared to the non-vaccinated ones. Circulation of PCV-2b in field trial A and PCV-2a plus PCV-2d in field trial B was confirmed by virus sequencing. Hence, the efficacy of this new trivalent vaccine against a natural PCV-2a, PCV-2b or PCV-2d challenge was demonstrated in terms of reduction of histopathological lymphoid lesions and PCV-2 detection in tissues, serum and faeces, as well as improvement of production parameters." @default.
- W4312126611 created "2023-01-04" @default.
- W4312126611 creator A5017368778 @default.
- W4312126611 creator A5018759343 @default.
- W4312126611 creator A5020386821 @default.
- W4312126611 creator A5025103823 @default.
- W4312126611 creator A5032124852 @default.
- W4312126611 creator A5037668600 @default.
- W4312126611 creator A5049197319 @default.
- W4312126611 creator A5054086491 @default.
- W4312126611 creator A5055956090 @default.
- W4312126611 creator A5062437918 @default.
- W4312126611 creator A5062815071 @default.
- W4312126611 creator A5065983156 @default.
- W4312126611 creator A5070333372 @default.
- W4312126611 creator A5073827597 @default.
- W4312126611 creator A5074638274 @default.
- W4312126611 creator A5078272302 @default.
- W4312126611 creator A5078514449 @default.
- W4312126611 creator A5081877092 @default.
- W4312126611 creator A5083872791 @default.
- W4312126611 date "2022-12-09" @default.
- W4312126611 modified "2023-10-18" @default.
- W4312126611 title "Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age" @default.
- W4312126611 cites W103161043 @default.
- W4312126611 cites W1967256901 @default.
- W4312126611 cites W1979958344 @default.
- W4312126611 cites W1989295132 @default.
- W4312126611 cites W2004808660 @default.
- W4312126611 cites W2011764123 @default.
- W4312126611 cites W2012713635 @default.
- W4312126611 cites W2015144268 @default.
- W4312126611 cites W2017412786 @default.
- W4312126611 cites W2020954544 @default.
- W4312126611 cites W2028900476 @default.
- W4312126611 cites W2029162595 @default.
- W4312126611 cites W2038527075 @default.
- W4312126611 cites W2040627816 @default.
- W4312126611 cites W2040943094 @default.
- W4312126611 cites W2043549172 @default.
- W4312126611 cites W2067312026 @default.
- W4312126611 cites W2069059203 @default.
- W4312126611 cites W2075095996 @default.
- W4312126611 cites W2091640911 @default.
- W4312126611 cites W2094051857 @default.
- W4312126611 cites W2122260755 @default.
- W4312126611 cites W2133423692 @default.
- W4312126611 cites W2136296701 @default.
- W4312126611 cites W2145085892 @default.
- W4312126611 cites W2146866564 @default.
- W4312126611 cites W2156462837 @default.
- W4312126611 cites W2157091665 @default.
- W4312126611 cites W2162244160 @default.
- W4312126611 cites W2165673174 @default.
- W4312126611 cites W2170184451 @default.
- W4312126611 cites W2181056332 @default.
- W4312126611 cites W2189401494 @default.
- W4312126611 cites W2208185712 @default.
- W4312126611 cites W2209205930 @default.
- W4312126611 cites W2338209007 @default.
- W4312126611 cites W2346071958 @default.
- W4312126611 cites W2429053348 @default.
- W4312126611 cites W2557832815 @default.
- W4312126611 cites W2573899163 @default.
- W4312126611 cites W2604680790 @default.
- W4312126611 cites W2751398085 @default.
- W4312126611 cites W2784889861 @default.
- W4312126611 cites W2896529920 @default.
- W4312126611 cites W2901842636 @default.
- W4312126611 cites W2904464741 @default.
- W4312126611 cites W2918755439 @default.
- W4312126611 cites W2964126884 @default.
- W4312126611 cites W2971572654 @default.
- W4312126611 cites W2973653590 @default.
- W4312126611 cites W2980878090 @default.
- W4312126611 cites W2997867944 @default.
- W4312126611 cites W3009058496 @default.
- W4312126611 cites W3022648361 @default.
- W4312126611 cites W3022798762 @default.
- W4312126611 cites W3185619038 @default.
- W4312126611 cites W3191075521 @default.
- W4312126611 cites W3193308938 @default.
- W4312126611 cites W4213390381 @default.
- W4312126611 cites W4289527300 @default.
- W4312126611 doi "https://doi.org/10.3390/vaccines10122108" @default.
- W4312126611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36560518" @default.
- W4312126611 hasPublicationYear "2022" @default.
- W4312126611 type Work @default.
- W4312126611 citedByCount "0" @default.
- W4312126611 crossrefType "journal-article" @default.
- W4312126611 hasAuthorship W4312126611A5017368778 @default.
- W4312126611 hasAuthorship W4312126611A5018759343 @default.
- W4312126611 hasAuthorship W4312126611A5020386821 @default.
- W4312126611 hasAuthorship W4312126611A5025103823 @default.
- W4312126611 hasAuthorship W4312126611A5032124852 @default.
- W4312126611 hasAuthorship W4312126611A5037668600 @default.
- W4312126611 hasAuthorship W4312126611A5049197319 @default.
- W4312126611 hasAuthorship W4312126611A5054086491 @default.